IDEAYA Biosciences (IDYA)
(Real Time Quote from BATS)
$29.46 USD
-0.51 (-1.70%)
Updated Oct 7, 2024 02:08 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for IDEAYA Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 23 | 51 | 28 | 20 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 23 | 51 | 28 | 20 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 158 | 113 | 78 | 55 | 44 |
Income After Depreciation & Amortization | -134 | -63 | -50 | -35 | -44 |
Non-Operating Income | 21 | 4 | 1 | 1 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -113 | -59 | -50 | -35 | -42 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -113 | -59 | -50 | -35 | -42 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -113 | -59 | -50 | -35 | -42 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -144 | -61 | -47 | -33 | -44 |
Depreciation & Amortization (Cash Flow) | -9 | 1 | 4 | 2 | 1 |
Income After Depreciation & Amortization | -134 | -63 | -50 | -35 | -44 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 57.52 | 41.45 | 35.25 | 24.72 | 12.50 |
Diluted EPS Before Non-Recurring Items | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 |
Diluted Net EPS (GAAP) | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 |
Fiscal Year end for IDEAYA Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 3.92 | 8.04 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 3.92 | 8.04 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 64.92 | 51.02 | 45.84 | 41.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -64.92 | -51.02 | -41.92 | -33.52 |
Non-Operating Income | NA | 12.16 | 11.45 | 7.96 | 6.09 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -52.77 | -39.57 | -33.96 | -27.44 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -52.77 | -39.57 | -33.96 | -27.44 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -52.77 | -39.57 | -33.95 | -27.44 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 77.96 | 75.11 | 65.25 | 60.00 |
Diluted EPS Before Non-Recurring Items | NA | -0.68 | -0.53 | -0.52 | -0.46 |
Diluted Net EPS (GAAP) | NA | -0.68 | -0.53 | -0.51 | -0.46 |